ArticleFrontiers in oncology2022
Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Primary splenic angiosarcoma with diffuse intrasinusoidal hepatic metastasis mimicking lymphoma: a diagnostic challenge.Clinical journal of gastroenterology · 2026Article
- Spontaneous hepatic rupture: A catastrophic complication in a patient with primary splenic angiosarcoma and hepatic metastasis: case report and literature review.Frontiers in oncology · 2025Article
- Case Report: A novel chemotherapy-free regimen combined with photodynamic therapy, target therapy, and immunotherapy in a geriatric male with huge recurrent scalp and facial angiosarcoma: a report of an extremely rare case and literature review.Frontiers in immunology · 2025Review
- Splenic angiosarcoma with hepatic and cardiac metastases: a case report and literature review.Frontiers in oncology · 2025Article
- Primary Epithelioid Angiosarcoma of the Jejunal Mesentery Causing Abdominal Bleeding: Case Report and Literature Review.OncoTargets and therapy · 2024Article
- Application value ofFrontiers in oncology · 2024Article
- Hepatic Angiosarcoma with Peliosis Hepatis.Internal medicine (Tokyo, Japan) · 2023Article
- Review
- Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.Journal of immunotherapy and precision oncology · 2023Article
- The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.Frontiers in immunology · 2022Review
- Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy.Frontiers in immunology · 2022Article
- Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57-year-old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.